• Explore /
  • Poster
  • / A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation.

A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation.

Abstract Poster

Authors

null

Elma S. Hawkins

Immunocellular Therapeutics, Ltd., Woodland Hills, CA

Elma S. Hawkins , Robert Aiken , James Chandler , Karen L. Fink , Michael J. Glantz , Jai Grewal , Michael L. Gruber , Santosh Kesari , Joseph C. Landolfi , Renato V. LaRocca , Glenn Jay Lesser , James Markert , Tina M. Mayer , Donald O'Rourke , David M. Peereboom , Surasak Phuphanich , David Schiff , Andrew E. Sloan , Baldassarre Stea , Jay-Jiguang Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT01280552

Citation

J Clin Oncol 30, 2012 (suppl; abstr TPS2107)

DOI

10.1200/jco.2012.30.15_suppl.tps2107

Abstract #

TPS2107

Poster Bd #

20F

Abstract Disclosures

Similar Posters

First Author: Jian Li Campian

First Author: Peijing Li

First Author: Maria Martinez-Garcia

First Author: Ulrich Herrlinger